Home  About us  Contact
 

La Tourette Syndrome (la + tourette_syndrome)

Distribution by Scientific Domains
Medical Sciences100%

Kinds of La Tourette Syndrome

  • Gille de la tourette syndrome
    		•
  • de la tourette syndrome
    		•

    Selected Abstracts

    Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP-CIT/SPECT study

    ACTA PSYCHIATRICA SCANDINAVICA, Issue 2 2004
    J. Serra-Mestres
    Objective:, To investigate dopamine transporter binding in Gilles de la Tourette syndrome (GTS) with SPECT and [123I]FP-CIT. Method:, Ten neuroleptic naïve/free patients with GTS, and 10 age- and gender-matched normal volunteers were studied. Subjects were clinically evaluated. GTS severity and affective symptoms were measured and the presence of GTS-related behaviours were recorded. Results:, The GTS group showed significantly higher binding in both caudate and putamen nuclei than the controls. No associations were found between striatal binding ratios and measures of affect or GTS-related behaviours. Conclusion:, Patients with GTS show higher striatal binding of FP-CIT to the striatum in comparison with age- and gender-matched control subjects, indicating that dopamine transporter abnormalities are involved in the pathophysiology of GTS. These abnormalities appear to be distributed across both caudate and putamen. [source]

    Complementary and alternative medicine use in Gilles de la Tourette syndrome

    MOVEMENT DISORDERS, Issue 13 2009
    Katie Kompoliti MD
    Abstract The aim of this study was to describe the use of complementary and alternative medicine (CAM) in patients with Tourette syndrome (TS) and explore associations with CAM use. In recent years CAM use has increased, but rates of CAM use in TS patients are not reported. Consecutive TS patients or their parent(s), seen in an academic movement disorder center, completed a questionnaire regarding their use of CAM. One hundred TS patients or parents completed the questionnaire, mean age 21.5 ± 13.5, 76 males, 87 Caucasians. Sixty four patients had used at least one CAM modality. CAM treatments used were prayer (28), vitamins (21), massage (19), dietary supplements (15), chiropractic manipulations (12), meditation (10), diet alterations (nine), yoga (nine), acupuncture (eight), hypnosis (seven), homeopathy (six), and EEG biofeedback (six). Fifty six percent of patients using CAM reported some improvement. Users paid out of pocket for 47% of treatments pursued, and 19% of these payers received partial reimbursement by third party payer. Users and non-users did not differ in age, gender, race, income, educational level, general health, tic severity, medication use for TS, current satisfaction from medications or experience of side effects from medications. CAM use was associated with the presence of affective disorder (P = 0.004), but not with either ADHD or OCD. Among CAM users, 80% initiated CAM without informing their doctor. CAM is commonly used in children and adults with TS, and often without the neurologist's knowledge. Physicians should inquire about CAM to understand the spectrum of interventions that patients with TS use. © 2009 Movement Disorder Society [source]

    Hassler and Dieckmann's seminal paper on stereotactic thalamotomy for Gilles de la Tourette syndrome: Translation and critical reappraisal,

    MOVEMENT DISORDERS, Issue 14 2008
    FRCPsych, Hugh Rickards MD
    Abstract Papers concerning the use of deep brain stimulation to the thalamus for relief of symptoms of Tourette syndrome have frequently cited a paper by Hassler and Dieckmann, published in 1970. We present a translation of this paper and discussion in English. © 2008 Movement Disorder Society [source]

    Aripiprazole: A treatment for severe coprolalia in "refractory" Gilles de la Tourette syndrome

    MOVEMENT DISORDERS, Issue 3 2008
    Mouna Ben Djebara MD
    Abstract Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28-year-old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics. © 2007 Movement Disorder Society [source]